openPR Logo
Press release

Bristol inks two combo deals after Opdivo miss - news addition by iData Insights

08-17-2016 10:17 AM CET | Health & Medicine

Press release from: iData Insights

www.omensol.wordpress.com

www.omensol.wordpress.com

Bristol inks two combo deals after Opdivo miss - news addition by iData Insights

Brief:

Bristol-Myers Squibb is testing its blockbuster immunotherapy Opdivo in two combinations with other oncology developers in an effort to further its combination strategy.

The big pharma has inked an early-stage collaboration with Aveo Oncology to test the biotech's once-daily, vascular endothelial growth factor tyrosine kinase inhibitor tivozanib with Opdivo, a PD-1 inhibitor.

Bristol-Myers will also supply Bavarian Nordic with a supply of Opdivo to test the drug in combination with the experimental CV301 in patients with non-small cell lung cancer (NSCLC).

Insight:

Despite a clinical setback last week for Opdivo (nivolumab) in the first-line setting of NSCLC, Bristol-Myers is undeterred in its pursuit of a strong clinical profile for the checkpoint inhibitor.

The big pharma has previously said it will focus on combination therapies including Opdivo to further differentiate the drug. Since its FDA approval last summer, Opdivo has quickly outpaced Merck's rival PD-1 inhibitor Keytruda (pembrolizumab), racking up sales and new indications. The failure in first-line NSCLC opens...
Read More: http://www.omensol.wordpress.com/hcp-updates/bristol/

For more info Contact:
Susana Simon
PA to MD
mark@idatainsights.com
1866-237-2965
+91 875 003 0003
Portland, OR
United States

iData Insights which operates under Precision Research and Consulting Pvt. Ltd. is a marketing research consulting firm. Its efforts help companies to create and improve products and services based on what the market desires. We conduct both primary and secondary research. Our work does not end with research. We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights
NE Airport Way, 355991,
Portland, Oregon, 97230
United States
Susana Simon
PA to MD
mark@idatainsights.com
1866-237-2965
+91 875 003 0003

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bristol inks two combo deals after Opdivo miss - news addition by iData Insights here

News-ID: 356785 • Views:

More Releases from iData Insights

PrivatePlus Mortgage Grows Management Team with Addition of Christine Conley Jr. in 2020
PrivatePlus Mortgage Grows Management Team with Addition of Christine Conley Jr. …
PrivatePlus Mortgage, a division of National Bank of Commerce, has named mortgage veteran Christine Conley Jr. as Senior Vice President, Operations. She oversees the overall Operations, ensuring loans are originated and processed according to PPM’s guidelines. “Christine has been in the mortgage industry for 30 years, serving in a broad range of positions, which gives her great perspective on each player’s role and what it ultimately means to our clients,” says
Insulin Market is Growing at 10.29% to 2019 - iData Insights
Insulin Market is Growing at 10.29% to 2019 - iData Insights
Insulin Market is Growing at 10.29% to 2019 - iData Insights According to the most up-to-data market data on the actual market situation and future outlook for insulin in the World, mainly in China, Denmark, France, Germany, India, Indonesia, Italy, Japan, Russia, and United States has shown the market is growing at 10.29% to 2019 and it is confirmed by iData Insights recently. Insulin Market is Growing at 10.29% to 2019 is
Insulin Market to 2019 - Market Size, Development, Top 10 Countries, and Forecasts
Insulin Market to 2019 - Market Size, Development, Top 10 Countries, and Forecas …
Insulin Market to 2019 - Market Size, Development, Top 10 Countries, and Forecasts The industry study package Insulin Market to 2019 - Market Size, Development, Top 10 Countries, and Forecasts offers the most up-to-date market data on the actual market situation, and future outlook for insulin in the world and in the top 10 global countries. Along with a global insulin market study the package includes country reports from the following
Oil & Gas Industry Google+ OMEN News Page Launch by Mark Stainer, iData Insights, to Help Oil & Gas Professionals to be Updated with the Major Happenings in the Industry
Oil & Gas Industry Google+ OMEN News Page Launch by Mark Stainer, iData Insights …
To Visit Google+ Oil & Gas Industry OMEN News Page, go to: plus.google.com/u/0/collection/kPRxbB iData Insights is pleased to announce that as part of its continuing social media outreach efforts, it has launched a Google+ Oil & Gas Industry OMEN News Page. The page will be used as hub of helpful News, Articles, Information for Oil & Gas Industry, providing Oil & Gas Industry Professionals with links to useful information that will

All 5 Releases


More Releases for Opdivo

OPDIVO Market  Global Industry Analysis By Size Estimation, Share, Business Gro …
"The most recent update of the "OPDIVO" includes Detailed Analysis and Key Data Factors on the OPDIVO as Considered by the Top Market Leaders in this Industry, Scope for Expansion and Geographic Outreach, and Overall Market Size for OPDIVO, as well as primary and secondary research and analysis of the important segments, market leading companies, and regions. The major market players involved in the industry, such as market participants, raw
Global OPDIVO Market: Which Region Is Anticipated To Benefit The Most? With Top …
The global OPDIVO market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global OPDIVO market. Analysts have used Porter’s five forces
Cancer Treatment Drugs Market to witness Exponential Growth during forecast peri …
Global Cancer Treatment Drugs Market Synopsis: Cancer is a disease, which includes the irregular rise of cells that results in the formation of a tumor. However benign tumors are not cancers. The abnormal tumor cells have the inclination to spread to other local tissues and may also spread to dissimilar parts of body through blood and lymphatic system. Different types of cancers such as lung cancer, colorectal, breast cancer, and others
Antibodies Market Set to Garner Staggering Revenues and Growing Demand During Fo …
The Antibodies market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional markets and also market competitors. The report estimates the performance of the key players by 2025 . Global Antibodies Market Overview: The report also reveals in-depth details of shifting market dynamics, pricing structures,
Immunotherapeutic Drugs Market 2020 will touch a new level in upcoming year 2025 …
The Immunotherapeutic Drugs market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional markets and also market competitors. The report estimates the performance of the key players by 2025. Global Immunotherapeutic Drugs Market Overview: The report also reveals in-depth details of shifting market dynamics, pricing structures,
PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology
Boston, MA ReportsWorldwide has announced the addition of a new report title PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology to its growing collection of premium market research reports. Since Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) first gained Japanese regulatory approval for the treatment of metastatic melanoma in July 2014, programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have grown to become the leading class of immunotherapies in oncology worldwide. Sales of the PD-1/PD-L1 therapy